Non-Hodgkin Lymphoma Clinical Trials

64 studies are recruiting for non-hodgkin lymphoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 3

1. AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

   This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UC Irvine Health, Orange, California

   Locations

   13 in total

   Run by

   Carna Biosciences, Inc.

   See if you can join NCT05602363 on ClinicalTrials.gov

2. Mozobil for Autologous Hematopoietic Stem Cell Transplantation

   This prospective trial investigates the approach of G-CSF with risk-adapted Plerixafor use for stem cell mobilization in patients undergoing autologous stem cell transplantation. Since FDA approval in 2008, Plerixafor has been combined with G-CSF to mobilize stem cells, though this regimen has been…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

   Run by

   Thomas Jefferson University

   See if you can join NCT07188090 on ClinicalTrials.gov

3. A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

   This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Kansas, Westwood, Kansas

   Locations

   7 in total

   Run by

   CRISPR Therapeutics AG

   See if you can join NCT05643742 on ClinicalTrials.gov

4. Auto Stem Cell Transplant for Lymphoma Patients

   This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.

   Stage

   Phase 2

   Ages

   Up to 75

   Site

   Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota

   Run by

   Masonic Cancer Center, University of Minnesota

   See if you can join NCT03125642 on ClinicalTrials.gov

5. Two Step Haplo With Radiation Conditioning

   This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however th…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadephia, Pennsylvania

   Run by

   Thomas Jefferson University

   See if you can join NCT05031897 on ClinicalTrials.gov

6. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Birmingham, Alabama

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov

7. Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

   This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant period to treat pediatric patients with relapsed or…

   Stage

   Phase 1

   Ages

   0 to 21

   Site

   University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

   Run by

   University of Wisconsin, Madison

   See if you can join NCT02508038 on ClinicalTrials.gov

8. Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

   This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor specific antibodies (DSA) levels to low enough levels to permit patie…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT06398457 on ClinicalTrials.gov

9. Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

   This is a phase Ib study to establish safety of Axi-Cel-2 in patients with Large B Cell Lymphoma (LBCL) who are at high risk of relapse.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stanford University, Palo Alto, California

   Run by

   Stanford University

   See if you can join NCT05794958 on ClinicalTrials.gov

10. Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

    The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relap…

    Stage

    Phase 2

    Ages

    3 to 31

    Site

    New York Medical College, Valhalla, New York

    Run by

    New York Medical College

    See if you can join NCT02393157 on ClinicalTrials.gov

11. AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

    Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.

    Stage

    Phase 2

    Ages

    0 to 30

    Site

    New York Medical College, Valhalla, New York

    Run by

    Mitchell Cairo

    See if you can join NCT04099966 on ClinicalTrials.gov

12. T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

    This is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of an autologous T-cell therapy (EB103) and to determine the Recommended Phase II Dose (RP2D) in adult subjects (≥ 18 years of age) who have relapsed/refractory (R/R) B-cell NHL. The study will incl…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, Davis, Sacramento, California

    Locations

    2 in total

    Run by

    Estrella Biopharma, Inc.

    See if you can join NCT06343311 on ClinicalTrials.gov

13. Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

    The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (c…

    Stage

    Phase 2

    Ages

    3 to 39

    Site

    University of Flordia, Gainsville, Florida

    Locations

    3 in total

    Run by

    New York Medical College

    See if you can join NCT05253495 on ClinicalTrials.gov

14. Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

    This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Goshen Center for Cancer Care, Goshen, Indiana

    Locations

    45 in total

    Run by

    Kartos Therapeutics, Inc.

    See if you can join NCT04502394 on ClinicalTrials.gov